Patheon, a business unit of DPx Holdings B.V., is a leading provider of contract development and commercial manufacturing (CDMO) services to the pharmaceutical and biotechnology sectors. The company offers one of the broadest sets of solutions to customers including commercial manufacturing, drug product services, biologics, pharmaceutical product development services and active pharmaceutical ingredients (API). 

With a reputation for quality, scientific technical excellence, the company has more than 20 locations and 8,000 employees across North America, Europe, Latin America and Australia.

Our integrated global network gives large or small biopharma companies instant access to comprehensive capabilities all over the world. We have 11 commercial-scale finished-dosage forms sites, four API process development and manufacturing sites, four biologics sites, and 10 formulation and process development sites to meet your needs at all phases of development.

4815 Emperor Blvd
Suite 300
Durham, NC 27703
Tel: 919-226-3200

Download Content

Implications of Inaccurate Forecasting on Biologics Drug Substance Manufacturing - White Paper
Finding New Formats for Good Old Protein A - Bottlenecking Solutions
Contract Biomanufacturing Firms Become More Specialized
Biopharma Advances Demand Specialized Expertise
Innovations, Trends and New Technologies in the Biopharmaceutical Industry
Lack of Expertise Hinders Adoption of Continuous API Synthesis
How Broadening the Analysis of Compound Factors Allows for Predictive Solubility Solutions - White Paper
Solid Dosage Outsourcing Trends
Technology Transfer Connections
The Timely Rise of the CDMO - White Paper


Increasing requests from regulatory agencies have focused on evaluation of APIs and drug products...
Learn about a novel, systematic methodology to accelerate solubilization of poorly soluble...
The biopharmaceutical industry has seen ever increasing innovation over the past five years. Most...

PharmTech News Articles

FDA issued a warning letter to Cixi Zhixin Bird Clean-Care Product Co., Ltd for violations of cGMP for finished pharmaceuticals.

The company announced an investment in a new facility in Dundalk, County Louth, Ireland.

Pharmco Laboratories received an FDA warning letter for significant violations of CGMP for finished drugs and APIs at its Florida, US facility as well as misbranding of over-the-counter (OTC) acne and sunscreen drug products.

Novo Nordisk entered a research collaboration with the University of Oxford focused on Type 2 diabetes.